Clinical trials: Sarcoma, Ewing
Ewing Sarcoma, Ewing Sarcoma of Bone
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
- Conditions
- Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT06068075
- Testing
- FoundationOne Liquid CDx
- Where
- 15 sites in United States
- Volunteers
- 340 people
- Sponsor
- Dana-Farber Cancer Institute
Osteosarcoma, Ewing Sarcoma
Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery
The objective of this study is to describe adherence to a personalised home exercise program in patients undergoing resection and reconstruction of lower limb for bone tumor and neoadjuvant chemotherapy treatment in the first six…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Bone Tumor
- Trial name
- ADER (NCT05779670)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Ortopedico Rizzoli
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Ewing
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression.
- Trial name
- NCT02657005
- Testing
- TK216
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Oncternal Therapeutics, Inc
Osteosarcoma, Ewing Sarcoma of Bone
Regorafenib in Patients With Refractory Primary Bone Tumors
The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options…
- Trial name
- Regbone (NCT05395741)
- Testing
- Regorafenib
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Institute of Mother and Child, Warsaw, Poland
Sarcoma
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Phase II trial to study the effectiveness of topotecan in treating children who have recurrent, relapsed, or refractory sarcoma.
- Trial name
- NCT00003745
- Testing
- topotecan hydrochloride
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 125 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Sarcoma
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer.
- Trial name
- NCT01492673
- Testing
- Cyclophosphamide, Topotecan, and Bevacizumab
- Where
- 7 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EWINGS SARCOMA
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
The purpose of this study is to examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory ES and rhabdomyosarcoma.
- Trial name
- Ewing/Allo (NCT02472392)
- Testing
- Rabbit anti-thymocyte globulin, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Louisville
Ewing's Sarcoma, Osteosarcoma
HGS-ETR2 to Treat Children With Solid Tumors
Background HGS-ETR2 is a monoclonal antibody, produced in the laboratory from human genes. HGS-ETR2 targets a protein called the TRAIL receptor that is located on the surface of some tumor cells.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
- Trial name
- NCT00428272
- Testing
- Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Neuroblastoma, Ewing Sarcoma
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.
- Trial name
- NCT06851221
- Testing
- beta3 expression
- Where
- Italy
- Volunteers
- 95 people
- Sponsor
- Meyer Children's Hospital IRCCS
Ewing's Sarcoma
Study in Localized and Disseminated Ewing Sarcoma
Ewing Sarcoma Primary objectives: Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients…
- Trial name
- EWING2008 (NCT00987636)
- Testing
- Zoledronic acid, Busulfan, Treosulfan
- Where
- 2 sites in Germany
- Volunteers
- 907 people
- Sponsor
- University Hospital Muenster
Sarcoma, Ewing, Sarcoma
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic…
- Trial name
- HopES (NCT03778996)
- Testing
- Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
This phase II trial study has a 6-patient feasibility portion studying the tolerability of chemotherapy with vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients…
- Conditions
- Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT00516295
- Testing
- topotecan hydrochloride, vincristine sulfate, cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma, Rhabdomyosarcoma
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection.
- Conditions
- Ewing's Sarcoma, Rhabdomyosarcoma, MPNST, Synovial Sarcoma
- Trial name
- NCT00004853
- Testing
- Filgrastim, Filgrastim-SD/01
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Bone Sarcoma, Chondrosarcoma
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects.
- Conditions
- Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone
- Trial name
- NCT05033288
- Testing
- Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Sarcoma
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
This study will examine the safety and effectiveness of stem cell transplantation for treating patients with sarcomas (tumors of the bone, nerves, or soft tissue).
- Trial name
- NCT00043979
- Testing
- F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
RATIONALE: Giving chemotherapy drugs, such as busulfan, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of tumor cells and prepares the patient's bone marrow for the stem cells.
- Trial name
- NCT00357396
- Testing
- graft versus host disease prophylaxis/therapy, busulfan, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center